# Opna Bio

**Canonical:** https://apis.io/providers/opna-bio/  
**Website:** https://www.opnabio.com  
**APIs profiled:** 0

Opna Bio is a clinical-stage biopharmaceutical company focused on oncology, developing novel small-molecule and targeted-degrader therapeutics against key regulators of cancer, including the Hallmarks of Cancer. Its pipeline features OPN-6602 (an EP300/CBP inhibitor in Phase 1 for multiple myeloma, granted FDA Fast Track designation), zavabresib (OPN-2853, a BET inhibitor with Orphan Drug designation for myelofibrosis), multi-functional protein degraders, and additional programs targeting hematologic malignancies and solid tumors. The company operates from South San Francisco and San Diego, California, and Lausanne, Switzerland.

## Kin Score — 11.2 / 100 (emerging)

Scored 2026-08-21 under rubric 0.12.0. Trend: flat (+0.0 from 11.2).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Opna Bio Domain Security** — DMARC

## Tags

Company, Oncology, Biopharmaceutical, Pharmaceuticals, Cancer, Drug Discovery, Life Sciences, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/opna-bio/). Scores are computed from the provider's own public artifacts under a published rubric.